CN111683950B - AhR调节剂 - Google Patents

AhR调节剂 Download PDF

Info

Publication number
CN111683950B
CN111683950B CN201980011943.5A CN201980011943A CN111683950B CN 111683950 B CN111683950 B CN 111683950B CN 201980011943 A CN201980011943 A CN 201980011943A CN 111683950 B CN111683950 B CN 111683950B
Authority
CN
China
Prior art keywords
methyl
trifluoromethyl
phenyl
quinazolin
pyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980011943.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111683950A (zh
Inventor
M·阿拉姆
H·P·贝克
M·P·狄龙
M·冈萨雷斯-洛佩兹
小J·C·萨顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idia Bioscience Co ltd
Original Assignee
Idia Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idia Bioscience Co ltd filed Critical Idia Bioscience Co ltd
Publication of CN111683950A publication Critical patent/CN111683950A/zh
Application granted granted Critical
Publication of CN111683950B publication Critical patent/CN111683950B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
CN201980011943.5A 2018-02-06 2019-02-05 AhR调节剂 Active CN111683950B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862626739P 2018-02-06 2018-02-06
US62/626,739 2018-02-06
US201962793260P 2019-01-16 2019-01-16
US62/793,260 2019-01-16
PCT/US2019/016705 WO2019156987A1 (en) 2018-02-06 2019-02-05 AhR MODULATORS

Publications (2)

Publication Number Publication Date
CN111683950A CN111683950A (zh) 2020-09-18
CN111683950B true CN111683950B (zh) 2024-04-16

Family

ID=65494575

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980011943.5A Active CN111683950B (zh) 2018-02-06 2019-02-05 AhR调节剂

Country Status (10)

Country Link
US (3) US10815250B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219495A1 (cg-RX-API-DMAC7.html)
JP (1) JP7382348B2 (cg-RX-API-DMAC7.html)
CN (1) CN111683950B (cg-RX-API-DMAC7.html)
CA (1) CA3090150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749669T6 (cg-RX-API-DMAC7.html)
ES (1) ES2946632T7 (cg-RX-API-DMAC7.html)
FI (1) FI3749669T6 (cg-RX-API-DMAC7.html)
TW (1) TWI840343B (cg-RX-API-DMAC7.html)
WO (1) WO2019156987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
KR20260057216A (ko) * 2019-11-22 2026-04-27 세일 바이오메디슨스, 인크. Ahr 길항제로서의 피리도피리미디논 유도체
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022081649A1 (en) * 2020-10-13 2022-04-21 Senda Biosciences, Inc. Biomarkers related to immune checkpoint inhibitor therapy and methods of using the same
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148350A1 (en) * 2009-06-18 2010-12-23 Cornell University Photoproducts of tryptophan, their synthesis and uses thereof
WO2015197861A1 (en) * 2014-06-27 2015-12-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2454080A1 (en) 2001-08-13 2003-02-27 Robert Edward Detlefsen Ultraviolet light absorbers
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2700988A1 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CN102105464A (zh) 2008-05-27 2011-06-22 德克萨斯大学系统董事会 Wnt蛋白信号转导抑制剂
MX2011009568A (es) 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
US10314810B2 (en) * 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148350A1 (en) * 2009-06-18 2010-12-23 Cornell University Photoproducts of tryptophan, their synthesis and uses thereof
WO2015197861A1 (en) * 2014-06-27 2015-12-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RN857834-18-5;ACS;《REGISTRY》;20050801;第1页 *

Also Published As

Publication number Publication date
CN111683950A (zh) 2020-09-18
EP4219495A1 (en) 2023-08-02
TWI840343B (zh) 2024-05-01
EP3749669A1 (en) 2020-12-16
FI3749669T6 (fi) 2024-11-13
US12258354B2 (en) 2025-03-25
JP2021512954A (ja) 2021-05-20
US20190270754A1 (en) 2019-09-05
JP7382348B2 (ja) 2023-11-16
US11407764B2 (en) 2022-08-09
ES2946632T7 (es) 2025-03-04
US20210002297A1 (en) 2021-01-07
CA3090150A1 (en) 2019-08-15
US20230039955A1 (en) 2023-02-09
US10815250B2 (en) 2020-10-27
FI3749669T3 (fi) 2023-05-26
TW201945362A (zh) 2019-12-01
WO2019156987A1 (en) 2019-08-15
ES2946632T3 (es) 2023-07-21
DK3749669T6 (da) 2024-11-18
EP3749669B1 (en) 2023-03-08
EP3749669B3 (en) 2024-09-04
DK3749669T3 (da) 2023-06-06

Similar Documents

Publication Publication Date Title
US12258354B2 (en) AhR modulators
TWI853802B (zh) 作為a2a/a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
CN114945571B (zh) 环状化合物及其使用方法
JP2020183397A (ja) Btk活性阻害剤としてのヘテロアリールピリドン及びアザピリドン化合物
KR20220100879A (ko) Fgfr 저해제로서의 이환식 헤테로사이클
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
JP2022525199A (ja) Eedおよびprc2調節物質としての大環状アゾロピリジン誘導体
EP4284804A1 (en) Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN119923398A (zh) 环状化合物和其使用方法
CN117120442A (zh) 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物
HK40042159B (en) Ahr modulators
CN117120447A (zh) 环状化合物和其使用方法
EA052528B1 (ru) Циклические соединения и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant